Gregory T. Lucier
MARAVAI LIFESCIENCES HOLDINGSAbout Gregory T. Lucier
Independent Class III director at Maravai LifeSciences Holdings (MRVI); age 60 as of March 24, 2025; on the board since the November 2020 IPO, with current term expiring at the 2026 Annual Meeting. He holds an MBA from Harvard Business School and a BA in Industrial Engineering from Pennsylvania State University. Career highlights include Chair and CEO of Life Technologies (2003–2014), CEO and Board Chair roles at NuVasive (CEO 2015–2018; Chair 2015–2021), and currently Executive Chairman and CEO of Corza Health, Inc. .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Life Technologies, Inc. | Chair and CEO | 2003–2014 | Led large-cap life sciences operator |
| NuVasive, Inc. | CEO; Chairman of the Board | CEO: 2015–2018; Chair: 2015–2021 | Oversaw minimally invasive spine surgery innovator |
| General Electric / GE Medical Systems IT | Corporate officer/executive | Early career (years not disclosed) | Operating and corporate leadership in health tech |
External Roles
| Organization | Role | Status/Tenure | Notes |
|---|---|---|---|
| Corza Health, Inc. | Executive Chairman and CEO | Current | Life sciences company leadership |
| Dentsply Sirona Inc. | Director | Current | Dental products/technologies |
| Catalent, Inc. | Director | 2015–2024 (until acquisition by Novo Holdings) | Pharma manufacturing |
| PhenomeX Inc. (formerly Berkeley Lights) | Director | Dec 2021–Sep 2023 (acquired by Bruker) | Life sciences tools |
| MLSH 1 (MRVI affiliate) | Board member | Since Jan 2020 | Governance of MRVI’s Up‑C structure entity |
Board Governance
- Independence: Board determined Lucier qualifies as an independent director under Nasdaq standards .
- Committee assignments: Not currently serving on Audit, Compensation and Leadership Development, or Nominating, Governance and Risk Committees .
- Attendance: In 2024, each director attended at least 75% of Board/committee meetings; all then‑serving directors attended the 2024 Annual Meeting .
- Board mix and structure: MRVI is a controlled company (GTCR holds majority voting power) and relies on controlled‑company exemptions for having committees not entirely composed of independent directors .
| Governance Item | Detail |
|---|---|
| Director Class & Term | Class III; Director since 2020; term expires 2026 |
| Independence Status | Independent (Nasdaq) |
| Committees | None at present |
| 2024 Meetings | Board: 8; Audit: 7; Comp: 6; Nom/Gov/Risk: 4 |
| Controlled Company | Yes; relies on exemptions for committee independence |
Fixed Compensation
| Component | 2024 Amount | Notes |
|---|---|---|
| Annual Board Cash Retainer | $60,000 | Standard MRVI non‑employee director retainer |
| Committee Fees (Chair/Member) | $0 | Not serving on committees; policy is Chair: Audit $25k; Comp $20k; Nominating $15k; Members: Audit $12.5k; Comp $10k; Nominating $7.5k |
| Meeting Fees | Not disclosed | Policy does not list meeting fees |
Performance Compensation
Directors receive equity grants structured as time-based RSUs; no performance metrics tied to director compensation are disclosed.
| Equity Award | Grant Date/Fair Value | Units/Status | Vesting |
|---|---|---|---|
| Annual Director RSU Award | $222,553 (May 23, 2024) | 20,645 RSUs unvested as of 12/31/2024 | Vests in full at the earlier of 1‑year anniversary or next Annual Meeting |
| Equity Program (policy) | ~ $200,000 FV annually | Applies to all non‑employee directors | As above; new director initial grant ~$400,000, vests over 3 years |
Other Directorships & Interlocks
- Current public boards: Dentsply Sirona (director) .
- Private/industry roles: Corza Health (Executive Chairman and CEO) .
- Potential interlocks/conflicts: No related‑party transactions involving Lucier disclosed; Audit Committee oversees and pre‑approves ordinary‑course related‑party transactions under policy; none listed specifically for Lucier .
- Controlled shareholder influence: GTCR has nomination and committee participation rights proportional to voting power under the Director Nomination Agreement .
Expertise & Qualifications
- Executive leadership and corporate governance expertise; C‑suite experience across life sciences and medical devices .
- Industry knowledge and strategy/M&A capabilities aligned with MRVI’s sectors .
- Education: MBA (Harvard), BS Industrial Engineering (Penn State) .
Equity Ownership
| Category | Amount/Status |
|---|---|
| Beneficial Ownership (Class A) | 75,768 shares; <1% of outstanding |
| Unvested Director RSUs | 20,645 RSUs (vest at Annual Meeting) |
| MLSH 1 Incentive Units | 9,600 vested; 2,400 unvested that vested Jan 8, 2025 |
| Ownership Guidelines | Directors: 4× annual board cash retainer |
| Hedging/Pledging | Prohibited by Insider Trading Policy |
Alignment signals: Time‑based RSUs with annual grants, no hedging/pledging permitted, and a hold‑to‑reach stock ownership guideline for directors .
Governance Assessment
- Strengths
- Independent director with deep life sciences operating experience; brings product, operations, and M&A oversight expertise .
- Director equity grants and ownership guidelines support alignment; hedging/pledging prohibited (reduces misalignment risk) .
- Broad external network from public and private boards may enhance information flow and strategic perspectives .
- Watch Items
- Controlled company status: Compensation and Nominating committees are not entirely independent, which can dilute minority shareholder protections; GTCR retains significant nomination rights and committee participation influence .
- Committee participation: Lucier does not sit on any Board committees, limiting his direct influence on Audit, Compensation, and Nominating oversight workstreams .
- Interlocks: Current executive role at Corza Health and directorship at Dentsply Sirona—while no related‑party transactions are disclosed, monitor for future commercial overlaps with MRVI’s customers/suppliers; Audit Committee screens transactions per policy .
- Shareholder feedback signals
- Say‑on‑pay (NEOs) received 97.83% support in 2024—positive governance signal though focused on executive pay rather than director compensation .
RED FLAGS
- Controlled company exemptions leading to committees not fully independent .
- Absence from committees reduces direct oversight contribution in critical governance areas .
Additional context for investors
- Attendance: All directors met at least the 75% threshold in 2024; all attended the 2024 Annual Meeting—adequate engagement baseline .
- Director cash/equity mix: 2024 compensation comprised $60,000 cash and $222,553 RSUs (time‑based), consistent with market practices; no meeting fees or performance‑based metrics disclosed .